doi: 10.1016/j.bmcl.2009.06.079.
Epub 2009 Jun 25.
Discovery of CYT997: a structurally novel orally active microtubule targeting agent
Affiliations
- PMID: 19616947
- DOI: 10.1016/j.bmcl.2009.06.079
Item in Clipboard
Discovery of CYT997: a structurally novel orally active microtubule targeting agent
Bioorg Med Chem Lett.
.
Abstract
CYT997 was discovered as a potent tubulin polymerization inhibitor possessing potent cytotoxic activity against a range of cancer cells. Details of SAR studies, pharmacokinetic investigations and synthesis of compounds leading to the discovery of CYT997 are reported.
Similar articles
-
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.Mol Cancer Ther. 2009 Nov;8(11):3036-45. doi: 10.1158/1535-7163.MCT-09-0076. Epub 2009 Nov 3. Mol Cancer Ther. 2009. PMID: 19887548
-
Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent.Invest New Drugs. 2013 Feb;31(1):126-35. doi: 10.1007/s10637-012-9813-y. Epub 2012 Mar 27. Invest New Drugs. 2013. PMID: 22451157 Clinical Trial.
-
Discovery and structure-activity relationships of (2-(arylthio)benzylideneamino)guanidines as a novel series of potent apoptosis inducers.Bioorg Med Chem. 2009 Apr 1;17(7):2852-8. doi: 10.1016/j.bmc.2009.02.029. Epub 2009 Feb 21. Bioorg Med Chem. 2009. PMID: 19282188
-
[Discovery of highly potent and orally active non-peptide bradykinin B2 receptor antagonists].Tanpakushitsu Kakusan Koso. 2000 Apr;45(6 Suppl):996-1000. Tanpakushitsu Kakusan Koso. 2000. PMID: 10771664 Review. Japanese. No abstract available.
-
Structure-based discovery and rational design of microtubule-targeting agents.Curr Opin Struct Biol. 2024 Aug;87:102845. doi: 10.1016/j.sbi.2024.102845. Epub 2024 May 27. Curr Opin Struct Biol. 2024. PMID: 38805950 Review.
Cited by
-
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.Br J Cancer. 2010 Aug 24;103(5):597-606. doi: 10.1038/sj.bjc.6605841. Br J Cancer. 2010. PMID: 20733579 Free PMC article. Clinical Trial.
-
The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins.Exp Ther Med. 2013 Aug;6(2):299-304. doi: 10.3892/etm.2013.1161. Epub 2013 Jun 14. Exp Ther Med. 2013. PMID: 24137178 Free PMC article.
-
Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis.J Mol Med (Berl). 2018 Sep;96(9):929-938. doi: 10.1007/s00109-018-1670-5. Epub 2018 Jul 18. J Mol Med (Berl). 2018. PMID: 30022281
-
Intracellular reduction in ATP levels contributes to CYT997-induced suppression of metastasis of head and neck squamous carcinoma.J Cell Mol Med. 2019 Feb;23(2):1174-1182. doi: 10.1111/jcmm.14017. Epub 2018 Nov 18. J Cell Mol Med. 2019. PMID: 30450674 Free PMC article.
-
Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.J Exp Clin Cancer Res. 2020 Jun 23;39(1):119. doi: 10.1186/s13046-020-01621-y. J Exp Clin Cancer Res. 2020. PMID: 32576206 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
